Evidence map›Paper›PMID 28660059›Full record

ArticleChemical science2016

Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases.

Tristan Reuillon, Sari F Alhasan, Gary S Beale, Annalisa Bertoli, Alfie Brennan, Celine Cano, Helen L Reeves, David R Newell, Bernard T Golding, Duncan C Miller and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Tristan ReuillonNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Sari F AlhasanNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Gary S BealeNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Annalisa BertoliNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Alfie BrennanNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Celine CanoNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Helen L ReevesNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
David R NewellNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Bernard T GoldingNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Duncan C MillerNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Roger J GriffinNewcastle Cancer Centre , Northern Institute for Cancer Research , School of Chemistry , Newcastle University , Bedson Building , Newcastle Upon Tyne , NE1 7RU , UK . Email: bernard.golding@newcastle.ac.uk ; Email: duncan.miller@ncl.ac.uk ; ; Tel: +44 (0)191 2226647.
Newcastle University · GBNewcastle upon Tyne Hospital · GBNational Cancer Centre Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibitors of sulfatase-2 are putative anticancer agents, but the discovery of potent small molecules targeting this enzyme has proved challenging. Based on molecular modelling, two series of sulfatase-2 inhibitors have been developed with biphenyl and biphenyl ether scaffolds judiciously substituted with sulfamate, carboxylate and other polar groups (

Identifiers

PMID28660059
PMCPMC5477036
OpenAlexW2237285042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.